Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07023289 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
A Phase 2 study of Colorectal Cancer, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT07023289 is a Phase 2 study of Colorectal Cancer that is actively recruiting participants, run by AbbVie. The registered enrollment target is 140 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT07023289, a Phase 2 study of Colorectal Cancer, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given alone. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. This study will be divided into two groups called treatment arms. In arm 1 participants will receive telisotuzumab adizutecan alone. In arm 2 participants will receive SOC alone. Approximately 140 adult participants with CRC will be enrolled in the study in 45 sites worldwide. In arm 1, participants will receive intravenous (IV) doses of telisotuzumab adizutecan alone. In arm 2 Participants will receive SOC alone. The study will run for a duration of approximately 51 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Conditions Studied
Interventions
- DRUG Telisotuzumab Adizutecan
- DRUG Standard of Care
Study Locations (20)
Texas
- Texas Oncology - Central/South Texas /ID# 275154 - Austin
- The Center For Cancer And Blood Disorders /ID# 278512 - Fort Worth
- Texas Oncology-Grapevine /ID# 275155 - Grapevine
- The University of Texas MD Anderson Cancer Center /ID# 273539 - Houston
California
- Providence Medical Foundation /ID# 274207 - Fullerton
- USC Norris Comprehensive Cancer Center /ID# 274550 - Los Angeles
Florida
- Mayo Clinic Hospital Jacksonville /ID# 274472 - Jacksonville
- Moffitt Cancer Center /ID# 274372 - Tampa
Minnesota
- Scri Minnesota Oncology Hematology, P.A. /ID# 275149 - Minneapolis
- Mayo Clinic-Rochester /ID# 273508 - Rochester
Virginia
- Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 274586 - Fairfax
- Virginia Cancer Specialists - Fairfax /ID# 274339 - Fairfax
Alabama
- Clearview Cancer Institute - Huntsville - Cci Drive /ID# 278621 - Huntsville
Illinois
- University of Chicago Medical Center /ID# 274742 - Chicago
Maryland
- Johns Hopkins Hospital /ID# 275645 - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2025-08-07 |
| Est. Completion | 2029-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07023289
The ClinicalTrials.gov registry entry for NCT07023289 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (91% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Telisotuzumab Adizutecan is the first listed.
NCT07023289 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT07023289 about?
NCT07023289 is a clinical study titled "A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease". Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given alone. Telisotuzumab adizutecan is an investigational drug bei...
What is the current status of trial NCT07023289?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2025-08-07. Estimated completion is 2029-11.
What conditions does trial NCT07023289 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT07023289?
The interventions under investigation include: Telisotuzumab Adizutecan (DRUG), Standard of Care (DRUG).
Who is sponsoring clinical trial NCT07023289?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07023289 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.